96.36Open96.36Pre Close0 Volume0 Open Interest160.00Strike Price0.00Turnover89.71%IV1.30%PremiumDec 20, 2024Expiry Date93.07Intrinsic Value100Multiplier19DDays to Expiry3.29Extrinsic Value100Contract SizeAmericanOptions Type0.9908Delta0.0005Gamma2.70Leverage Ratio-0.0507Theta0.0815Rho2.68Eff Leverage0.0143Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet